NEW YORK, June 10, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit
has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased NewLink Genetics
Corporation (NASDAQ:NLNK) securities between September 17, 2013 and May 9, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/newlink-genetics-corporation. There is no cost or
obligation to you.
According to the complaint, NewLink continuously touted the effectiveness and favorable safety profile of the
company’s lead product candidate, algenpantucel-L, an immunotherapeutic pancreatic cancer treatment. As a result of such public
statements, the stock price traded at artificially high levels throughout the class period.
On May 9, 2016, NewLink announced that algenpantucel-L did not achieve its primary endpoint. Patients treated
with algenpantucel-L lived for a median of 27.3 months in NewLink’s Phase 3 Clinical Trial, compared to median survival of 30.4
months for patients treated with standard therapy. Following this news, shares of NewLink were down more than 30% during intraday
trading May 10, 2016.
If you suffered a loss in NewLink you have until July 11, 2016 to request that the Court appoint you as lead
plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional
information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/newlink-genetics-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving
financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: vw@wongesq.com
